September, 2016:
- Lenalidomide Maintenance Recommended in Myeloma Post-transplant
- ASTRO: Study Affirms Efficacy of Doxepin Rise for Treatment of Oral Mucositis Pain
- Adding CVP ± Rituximab After IFRT Improves PFS vs IFRT Alone in Stage 1-2 Follicular Lymphoma
- Calcifications Linked With Favorable, Unfavorable Prognostic Factors in Breast Cancer
- Height and Melanoma Risk: What's the Takeaway?
- Metastasis More Than Doubles With Monitoring Instead of Treatment for Localized Prostate Cancer
- Use of SBRT Improves OS Rates Among Veterans With Stage I NSCLC
- Tumor-specific Biomarkers Predict Response in HER-2-positive Breast Cancer
- Survival Rate Rising Among Elderly Patients With NSCLC Treated With SBRT
- The Next Frontier: Radiotherapy Plus Immunotherapy for Melanoma Brain Metastases
- Carfilzomib + Melphalan, Prednisone Fails to Improve PFS in Myeloma
- Encorafenib + Binimetinib Improves PFS Versus Vemurafenib Alone in Melanoma
- Combination Therapy May Improve Survival in Nasopharyngeal Carcinoma
- No Difference in PFS Between RT and Temozolomide in Glioma
- Q&A With Samanta Kumar Pal, MD: Prostate Cancer Androgen Deprivation and "Drug Holidays"
- Defibrotide for Hepatic Sinusoidal Obstruction Syndrome in Hematopoietic Stem Cell Transplant
- PSA Testing Unchanged in Years After USPSTF Recommendation
- MRI May Be Effective Screening Test for Hepatocellular Carcinoma
- Risk of Arrhythmias, Bleeding Higher With Ibrutinib Therapy
- Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP
- Emerging Prognostic Markers Continue to Improve Myeloma Treatment
- Study Emphasizes Importance of Skin Exams for Organ Transplant Recipients
- Alpha-fetoprotein Levels May Predict HCC Response to Ramucirumab
- TP53, MDM2 Alterations Linked to Cisplatin Resistance in Testicular Cancer
- Post-mastectomy Radiotherapy Reduces Risk for Locoregional Failure, Recurrence
- Circulating Plasma Cells Predict Poor Prognosis in Multiple Myeloma
- Combined Treatment May Lead to Cure for Chronic Myeloid Leukemia
- Response Rate Similar Between Low- and Standard-dose Ponatinib
- Ibrutinib Linked With Favorable Survival, High Response Rate in CLL
- Imatinib Less Beneficial for Patients With CML in Accelerated Phase
- Q&A With Dr Sarah Vinnicombe: Use Breast MRI Judiciously for Optimal Outcomes
- Ghost and Honorary Authorship in Cancer Research
- Coping With Waldenstrom Macro-globulinemia
- FDA Accepts NDA for Neratinib in HER2+ Early Stage Breast Cancer
- Bevacizumab Not Recommended in Adjuvant Colorectal Cancer Treatment
- Dalantercept Monotherapy Study Misses Endpoint
- Addition of Rituximab to Chemo Provides Survival Benefit in Acute Leukemia
- Immunotherapy-related Pneumonitis More Common With Combo Therapy
- Statins Linked to Improved Overall Survival in Multiple Myeloma
- Treating TKI-induced Hypertension in Renal Cell Carcinoma
- Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC
- G-CSF Linked With Some Reduction in Neutropenia-related Hospitalization
- Population Disparity in NCI Studies Still Needs Improvement
- CTA Treatment Regimen Chart for Esophageal and EGJ Cancers Updated
- Fixed-dose Pembrolizumab Induces Durable Responses in HNSCC
- Oral REP Regimen Active in Myeloma Refractory to Lenalidomide
- Vasectomy Unlikely to Be a Causal Factor of Aggressive Prostate Cancer
- Minimal Residual Disease and Treatment Response in Multiple Myeloma
- Decline in Use of Digital Rectal Examination, PSA Testing
- Recent Decline in Cancer Mortality Among Teenagers, Children
- Testosterone Appears Safe for Hypogonadal Patients With Prostate Cancer
- 2016 Concordia Summit: The Future of Immunotherapy
- Ricolinostat Appears Safe in Relapsed/Refractory Myeloma
- Massage Therapy May Reduce Chemo-induced Peripheral Neuropathy
- FDA Modifies Nivolumab Dosage Regimens for RCC, NSCLC, Melanoma
- MRD-negative Status Linked With Better Survival in Multiple Myeloma
- Lenalidomide Active in R/R Adult T-cell Leukemia/Lymphoma
- Overspending on Antiemetic Drugs Not Decreasing, Despite ASCO Guidelines
- Q&A With Dana Carroll, PhD, Highlights CRISPR's Growing Role in Genome Editing
- Metabolic Tumor Volume Predicts Outcome in Follicular Lymphoma
- Everolimus Associated With Longest mOS Observed Among Patients With Advanced pNET
- Prostate Cancer Mortality May Be Consistent Regardless of Treatment Choice
- Assessing Mindfulness-based Cognitive Therapy For Cancer Pain
- Urinary, Sexual Function Vary by Treatment Type in Localized Prostate Cancer
- Ibrutinib Active in Patients With R/R CLL and 17p Deletion
- Dexamethasone-based Mouthwash for Stomatitis Prevention
- Uridine Triacetate May Be Safe, Effective Treatment for Capecitabine/5-FU Overdose
- Cabazitaxel Active in Docetaxel-resistant Non-small Cell Lung Cancer
- The Evolutionary Implications of CRISPR-Cas9 for Clinical Oncology
- Enforcing Reproducibility Improves the Accuracy of Scientific Predictions
- Second-line mFOLFOX6 and FU/LV for Pancreatic Cancer
- Adding Palifosfamide to Doxorubicin Fails to Improve PFS in Sarcoma
- Strategies for Treatment of Patients With Ductal Carcinoma in Situ Evaluated
- Use of Higher SPF Sunscreen Linked With Lower Melanoma Risk
- Olaparib Maintenance Fails to Significantly Prolong Survival in Ovarian Cancer
- Effective Patient-Oncologist Communication Training Recommended
- Phase 2 CheckMate 069 Study Suggests Nivolumab Plus Ipilimumab May Improve Overall Survival in Melanoma
- Chronic Sinusitis Linked With Head and Neck Cancers
- Endoscopic Ultrasound and Pancreatic Cancer Screening
- FDA Grants Priority Review to Pembrolizumab for Frontline Treatment of NSCLC
- Afatinib Dose Adjustment Improves Tolerability Without Affecting Efficacy in NSCLC
- Cord-blood Transplant Donations Improve Survival of Patients With Acute Leukemia or Myelodysplastic Syndrome
- Combination Immunotherapy Promising for Treatment of Renal Cell Carcinoma
- TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI
- KRd Improves QoL vs Rd Alone in Multiple Myeloma
- Overdetection Explains Increased Prevalence of Thyroid Cancer
- Checkpoint Inhibitors and Combination Therapy: the Future of Treatment for Non-small Cell Lung Cancer?
- Breast Cancer Risk and Psychosocial Adjustment Among Adolescents
- Integrating Palliative Care Early Improves QOL of Patients With Incurable Cancer
- "Mystery Shopper" Study Identifies Barriers to Palliative Care Access
- VEGF/mTOR-directed Combination Shows Promise in Renal Cell Carcinoma
- Biological Implications of Obesity Linked to Survival of Patients With Renal Cell Carcinoma
- CTA Treatment Regimen Chart for Melanoma Updated
- Selinexor Effects Responses in Refractory Myeloma
- Avelumab Induces Durable Responses in Merkel Cell Carcinoma
- Whole Brain Radiotherapy Offers Little Benefit to Patients With Brain-metastatic Lung Cancer
- Mortality From Ovarian Cancer on Decline in the West
- Melanoma Treatment Regimens
- Atezolizumab Significantly Improves OS in Locally Advanced or Metastatic NSCLC
- FDA Approves Blinatumomab for Pediatric B-cell Precursor ALL
- ADI-PEG20 Improves PFS in ASS1-deficient Mesothelioma
- Vandetanib Fails to Benefit Patients With Small Cell Lung Cancer
- Managing PD-1 Inhibitor-induced Pneumonitis
- Ongoing ADT Use Up to 36 Months Not Linked With Cognitive Decline
- Mortality Risk Higher With Genetic Duet in Papillary Thyroid Cancer
- Dronabinol Oral Solution Approved for CINV
- Enoxaparin Reduces Occurrence of Venous Thromboembolic Events
- Age May be Prognostic Factor in Ovarian Cancer
- Breast Density and Risk Factors Indicate Breast Cancer Screening Intervals
- Bone Marrow Transplantation as a Treatment Option: What You Need to Know
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Prostate Cancer | Regimens | Drugs |
Rare Cancers | Regimens | |
Renal Cell Carcinoma | Regimens | Drugs |
Skin Cancer | Regimens | Drugs |
Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL
- Bloodroot and Cancer
- Perioperative Gabapentin May Improve Pain Management in Head and Neck Cancer
- ACA Decreased Non-Insurance Rates Among Patients With Head and Neck Cancer
- Acetaminophen May Decrease Opioid Use After Head and Neck Cancer Surgery